Hologic weakness a buying opportunity, says Barrington Barrington said the weakness in Hologic following slightly weaker Q1 results is a buying opportunity and that fundamentals remain intact. Shares are Buy rated with a $26 price target.
News For HOLX From The Last 14 Days
Check below for free stories on HOLX the last two weeks.
Hologic receives FDA approval for low-dose 3D mammography solution Hologic announced that the FDA approved the use of Hologic's new C-View 2D imaging software. C-View 2D images may now be used in place of the conventional 2D exposure previously required as part of a Hologic 3D mammography screening exam.
Leerink's medical devices analyst holds a conference call Medical Devices Analyst Newitter discusses Hologic's tomosynthesis (3D) technology on an Analyst/Industry conference call to be held on May 16 at 2:30 pm.
Subscribe for More Information